These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35488820)

  • 1. Ceftobiprole medocaril.
    Méndez R; Latorre A; González-Jiménez P
    Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):25-27. PubMed ID: 35488820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.
    Drugs R D; 2006; 7(5):305-11. PubMed ID: 16922591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftobiprole medocaril for the treatment of community-acquired pneumonia.
    Falcó V; Burgos J; Almirante B
    Expert Opin Pharmacother; 2018 Sep; 19(13):1503-1509. PubMed ID: 30198789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of action and antimicrobial activity of ceftobiprole.
    Morosini MI; Díez-Aguilar M; Cantón R
    Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):3-10. PubMed ID: 31364335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.
    Syed YY
    Drugs; 2014 Sep; 74(13):1523-42. PubMed ID: 25117196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftobiprole medocaril for the treatment of pneumonia.
    Hsu WH; Hsu CK; Lai CC
    Expert Rev Anti Infect Ther; 2023 Jun; 21(6):551-563. PubMed ID: 37042813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Dauner DG; Nelson RE; Taketa DC
    Am J Health Syst Pharm; 2010 Jun; 67(12):983-93. PubMed ID: 20516468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
    Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
    Anderson SD; Gums JG
    Ann Pharmacother; 2008 Jun; 42(6):806-16. PubMed ID: 18477729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
    Barbour A; Schmidt S; Rand KH; Derendorf H
    Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftobiprole for the treatment of pneumonia: a European perspective.
    Liapikou A; Cillóniz C; Torres A
    Drug Des Devel Ther; 2015; 9():4565-72. PubMed ID: 26316697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftobiprole medocaril: a new generation beta-lactam.
    Del Pozo JL; Patel R
    Drugs Today (Barc); 2008 Nov; 44(11):801-25. PubMed ID: 19180259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftobiprole: a new broad spectrum cephalosporin.
    El Solh A
    Expert Opin Pharmacother; 2009 Jul; 10(10):1675-86. PubMed ID: 19527192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of ceftobiprole.
    Grau S
    Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):34-36. PubMed ID: 31364340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Vidaillac C; Rybak MJ
    Pharmacotherapy; 2009 May; 29(5):511-25. PubMed ID: 19397461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.
    Awad SS; Rodriguez AH; Chuang YC; Marjanek Z; Pareigis AJ; Reis G; Scheeren TW; Sánchez AS; Zhou X; Saulay M; Engelhardt M
    Clin Infect Dis; 2014 Jul; 59(1):51-61. PubMed ID: 24723282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.
    Horn KS; Danziger LH; Rodvold KA; Glowacki RC
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):463-472. PubMed ID: 28264613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
    Fernandez J; Hilliard JJ; Abbanat D; Zhang W; Melton JL; Santoro CM; Flamm RK; Bush K
    Antimicrob Agents Chemother; 2010 Jan; 54(1):116-25. PubMed ID: 19884364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
    Lodise TP; Low DE
    Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia.
    Scheeren TW
    Future Microbiol; 2015; 10(12):1913-28. PubMed ID: 26573022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.